DOCSLIB.ORG

CMS: High-Risk Medications (Relevant for Older People Defined As Greater Than 65 Years of Age)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CMS: High-Risk Medications (Relevant for Older People Defined As Greater Than 65 Years of Age) CMS: High-Risk Medications (Relevant for older people defined as greater than 65 years of age) Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Amphetamines amphetamine & dextroamphetamine (H) CNS stimulation: agitation, insomnia; Consider discontinuing (ADDERALL/XR ) hypertension, myocardial ischemia; benzphetamine (H) (DIDREX ) dependence; appetite suppression dexmethylphenidate (H) (FOCALIN/XR ) dextroamphetamine (H) (DEXADRINE, DEXTROSTAT ) diethylpropion (H) (DURAD, TENUATE, TEPANIL ) INTUNIV (H) methamphetamine (H) (DESOXYN ) methylphenidate (H) (RITALIN/LA, CONCERTA, DAYTRANA, METADATE CD ) phendimetrazine (H) (BONTRIL ) phentermine (H) (ADIPEX-P ) Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Analgesics indomethacin (INDOCIN) Ketorolac: Gastrointestinal bleeding risk mild pain: ketorolac (H) (TORADOL ) increased in elderly. APAP ibuprofen Indomethacin: GI bleeding/peptic ulcer in high- naproxen risk patients.a Has more adverse effects than meloxicam other NSAIDs. Edema may worsen heart failure. moderate/severe pain: tramadol morphine sulfate (MS CONTIN) hydrocodone/APAP(V ICODIN , etc) oxycodone (OXYIR) oxycodone/APAP (PERCOCET) fentanyl patch (DURAGESIC) OXYCONTIN AVINZA use lowest dose possible to avoid side effects and reduce pain Anti-adrenergics guanabenz Orthostatic hypotension, bradycardia, CNS HCTZ guanfacine (TENEX) adverse effects lisinopril methyldopa (ALDOMET) enalapril methyldopa/HCTZ (ALCOLOR, ALDORIL) losartan metoprolol Anti-anxiety meprobamate (H) (EQUINIL ) Dependence; sedation; depression; confusion; anxiety: aspirin/meprobamate (H) (EQUAGESIC ) falls; fractures; respiratory depression buspirone (BUSPAR) (especially in COPD) sleep: ROZEREM Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Anti-emetics trimethobenzamide (H) (TIGAN ) Anticholinergic side effects: worsened TRANSDERM-SCOP promethazine (H) (PHENERGAN) cognition & behavioral problems (especially in ondansetron (ZOFRAN) dementia); urinary retention OR incontinence; granisetron (KYTRIL) questionable efficacy prochlorperazine (COMPAZINE) metoclopramide (REGLAN)* *avoid using long-term and/or in Parkinson’s disease Antihistamines APAP/dextromethorphan/diphenhydramine (H) Anticholinergic side effects: worsened Levocetirizine (XYZAL) APAP/diphenhydramine/phenylephrine (H) cognition & behavioral problems (especially in CLARINEX APAP= APAP/diphenhydramine/PSE (H) dementia); urinary retention OR incontinence; acetaminophen APAP & diphenhydramine (H) confusion; enhanced sedation; PSE= Brompheniramine / combination products (H) pseudoephedrine carbetapentane/diphenhydramine/ phenylephrine (H) carbinoxamine / combination products (H) chlorpheniramine / combination products (H) clemastine (H) codeine/promethazine/phenylephrine (H) codeine & promethazine (H) cyproheptadine (H) dexbrompheniramine-Pyrilamine (H) dexchlorpheniramine dexchlorpheniramine/dextromethorphan/PSE (H) dexchlorpheniramine/guaifenesin/PSE (H) dexchlorpheniramine/hydrocodone/ phenylephrine (H) dexchlorpheniramine/methscopolamine/PSE (H) dexchlorpheniramine & PSE (H) dextromethorphan & promethazine (H) diphenhydramine (H) diphenhydramine/hydrocodone/ phenylephrine (H) diphenhydramine & phenylephrine (H) diphenhydramine & PSE (H) diphenhydramine & magnesium salicylate (H) doxylamine hydroxyzine hydrochloride (H) hydroxyzine pamoate (H) phenylephrine & promethazine (H) promethazine (H) triprolidine Note: Various brand name drugs apply. Antihistamines APAP/dextromethorphan/diphenhydramine (H) Anticholinergic side effects: worsened Levocetirizine (XYZAL) APAP/diphenhydramine/phenylephrine (H) cognition & behavioral problems (especially in CLARINEX APAP= APAP/diphenhydramine/PSE (H) dementia); urinary retention OR incontinence; acetaminophen APAP & diphenhydramine (H) confusion; enhanced sedation; PSE= Brompheniramine / combination products (H) pseudoephedrine carbetapentane/diphenhydramine/ phenylephrine (H) carbinoxamine / combination products (H) chlorpheniramine / combination products (H) clemastine (H) codeine/promethazine/phenylephrine (H) codeine & promethazine (H) cyproheptadine (H) dexbrompheniramine-Pyrilamine (H) dexchlorpheniramine dexchlorpheniramine/dextromethorphan/PSE (H) dexchlorpheniramine/guaifenesin/PSE (H) dexchlorpheniramine/hydrocodone/ phenylephrine (H) dexchlorpheniramine/methscopolamine/PSE (H) dexchlorpheniramine & PSE (H) dextromethorphan & promethazine (H) diphenhydramine (H) diphenhydramine/hydrocodone/ phenylephrine (H) diphenhydramine & phenylephrine (H) diphenhydramine & PSE (H) diphenhydramine & magnesium salicylate (H) doxylamine Drug High-risk agents to Avoid Non-high risk alternatives hydroxyzine hydrochloride (H) Reason for Risk classification hydroxyzine(H) =pamoate considered (H) Highest-risk¹ Drug phenylephrine & promethazine (H) promethazine (H) triprolidine Note: Various brand name drugs apply. Antiparkinson/ benztropine (COGENTIN) Delirium, worsen cognitive impairment, worsen Consider discontinuing or using atypical antipsychotics trihexyphenidyl constipation, worsen urinary retention; not antipsychotic recommended to prevent antipsychoticassociated extrapyramidal effects; not very effective for Parkinson’s disease Antipsychotics thioridazine (H) (MELLARIL ) CNS side effects; seizure risk; extrapyramidal haloperidol (HALDOL) effects: tremor, slurred speech, muscular risperidone (RISPERDAL)* rigidity, dystonia (involuntary muscle ABILIFY* contractions), bradykinesia (slowing of FANAPT* movement), akathisia (inability to sit/stand still) GEODON* INVEGA* SEROQUEL* ZYPREXA* *atypical antipsychotics associated w/ increased mortality when used to treat behavioral issues in elderly w/ dementia Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Barbiturates butabarbital (H) (BUTISOL ) Higher risk of side effects: falls; fractures; sleep: butalbital / combinations (H) (FIORICET, confusion; cognitive impairment; dependence ROZEREM FIORINAL, DOLGIC, ESGIC) mephobarbital (H) (MEBARAL ) mild pain: pentobarbital (H) (NEMBUTAL ) APAP phenobarbital (H) (LUMINAL) ibuprofen naproxen secobarbital (H) (SECONAl) meloxicam moderate/severe pain: tramadol morphine sulfate (MS CONTIN) hydrocodone/APAP (VICODIN, etc) oxycodone (OXYIR) oxycodone/APAP (PERCOCET) fentanyl patch (DURAGESIC) OXYCONTIN AVINZA Belladona alkaloids atropine/hyoscyamine/phenobarbital/ Anticholinergic AEs: worsened cognition & constipation: scopolamine (H) (BELLADONNA ALKALOIDS, behavioral problems (especially in dementia); psyllium fiber (METAMUCIL) CPM= DONNATAL, ANTISPASMODIC ELIXIR) urine retention; agitation & delirium polyethylene glycol (MIRALAX) chlorpheniramine atropine & edrophonium (ENLON) docusate belladonna (H) PE=phenylephrine belladonna/ergotamine/phenobarbital (H) diarrhea: (BELLAMINE ) loperamide (IMODIUM) butabarbital/hyoscyamine/phenazopyridine (H) aluminum hydroxide (PHENAZOPYRIDEINE PLUS, atropine & difenoxin (MOTOFEN ) PHENAZOFORTE PLUS) atropine & diphenoxylate digestive- enzymes/ hyoscyamine/ (LOMOTIL, LONOX, LOGEN, phenyltoloxamine (H) (DIGEX NF) LOMANATE ) Benzodiazepines amitriptyline & chlordiazepoxide (H) (LIMBITROL Dependence; depression; prolonged sedation; buspirone (BUSPAR) (long-acting) DS ) confusion; falls; fractures; respiratory chlordiazepoxide (H) (LIBRIUM ) depression (especially in COPD); accumulation diazepam (VALIUM ) of drug flurazepam (DALMANE ) Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Calcium channel nifedipine (short-acting immediate release only) Hypotension; constipation nifedipine ER (PROCARDIAXL) blockers (H) (ADALAT CC, PROCARDIA ) Cardiac glycosides digoxin (LANOXIN, DIGITEK, LANOXICAPS) No additional efficacy vs lower doses; toxicity Consider discontinuing or dose reduction due to reduced renal clearance (e.g. 0.125mg) with monitoring Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Estrogens and Oral Increased risk of breast &/or endometrial Hot flashes*: progestins ANGELIQ cancer; NOT cardioprotective venlafaxine (EFFEXOR) conjugated estrogen (PREMARIN, ESTINYL) paroxetine (PAXIL) conjugated estrogen & medroxyprogesterone fluoxetine (PROZAC) (PREMPRO, PREMPHASE) sertraline (ZOLOFT) esterified estrogen (MENEST ) gabapentin esterified estrogen & methyltestosterone (H) * nondrug therapy should be emphasized (COVARYX, ESTRATEST) Bone density: estropipate (OGEN, ORTHO-EST) Calcium vitamin D estradiol (H) (ESTRACE, GYNODIOL) (H) alendronate (FOSAMAX) estradiol/norethindrone (H) (ACTIVELLA, ACTONEL MIMVEY) Ibandronate (BONIVA) FEMHRT (H) EVISTA JEVANTIQUE (H) JINTELI (H) Genitourinary symptoms: Megestrol (MEGACE/ES) (H) Femring ORTHOPREFEST (H) Premarin vaginal cream PREFEST (H) Vagifem Transdermal estradiol patch (H) ALORA patch (H) ESTRASORB (H) ESCLIM patch (H) CLIMARA PRO patch (H) COMBIPATCH (H) VIVELLE-DOT patch (H) MENOSTAR patch (H) DIVIGEL topical gel (H) ELESTRIN topical gel (H) EVAMIST topical spray (H) Drug High-risk agents to Avoid Non-high risk alternatives Reason for Risk classification (H) = considered Highest-risk¹ Drug Narcotics ASA/caffeine/propoxyphene (DARVON Enhanced CNS effects: confusion, mild pain: COMPOUND ) hallucinations; falls;
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Product Information
    PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE® (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine with anticholinergic properties Dexchlorpheniramine maleate (CAS no. 2438-32-6) is described chemically as (+)-2-[p- chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine maleate (1:1). It has the empirical formula of C16H19ClN2.C4H4O4 and the following structural formula: Dexchlorpheniramine maleate is a white, odourless, crystalline powder which in aqueous solution has a pH of between 4 and 5. It is freely soluble in water, soluble in alcohol and in chloroform, but only slightly soluble in benzene or ether. PHARMACOLOGY Pharmacodynamics Mechanism of Action: Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. H1-antagonists are structurally similar to anticholinergic agents and therefore possess the potential to exhibit anticholinergic properties of varying
    [Show full text]
  • Report Update 1
    Drug Class Review on Newer Antihistamines Final Report Update 1 April 2006 Original Report Date: November 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior version of this report can be accessed at the DERP website. Final Report Update #1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION.............................................................................................................................................................4 SCOPE AND KEY QUESTIONS.............................................................................................................................6
    [Show full text]
  • Drugs to Avoid in Patients with Dementia
    Detail-Document #240510 -This Detail-Document accompanies the related article published in- PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2008 ~ Volume 24 ~ Number 240510 Drugs To Avoid in Patients with Dementia Elderly people with dementia often tolerate drugs less favorably than healthy older adults. Reasons include increased sensitivity to certain side effects, difficulty with adhering to drug regimens, and decreased ability to recognize and report adverse events. Elderly adults with dementia are also more prone than healthy older persons to develop drug-induced cognitive impairment.1 Medications with strong anticholinergic (AC) side effects, such as sedating antihistamines, are well- known for causing acute cognitive impairment in people with dementia.1-3 Anticholinergic-like effects, such as urinary retention and dry mouth, have also been identified in drugs not typically associated with major AC side effects (e.g., narcotics, benzodiazepines).3 These drugs are also important causes of acute confusional states. Factors that may determine whether a patient will develop cognitive impairment when exposed to ACs include: 1) total AC load (determined by number of AC drugs and dose of agents utilized), 2) baseline cognitive function, and 3) individual patient pharmacodynamic and pharmacokinetic features (e.g., renal/hepatic function).1 Evidence suggests that impairment of cholinergic transmission plays a key role in the development of Alzheimer’s dementia. Thus, the development of the cholinesterase inhibitors (CIs). When used appropriately, the CIs (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Razadyne, Reminyl in Canada]) may slow the decline of cognitive and functional impairment in people with dementia. In order to achieve maximum therapeutic effect, they ideally should not be used in combination with ACs, agents known to have an opposing mechanism of action.1,2 Roe et al studied AC use in 836 elderly patients.1 Use of ACs was found to be greater in patients with probable dementia than healthy older adults (33% vs.
    [Show full text]
  • Nomination Background: Ketamine Hydrochloride (CASRN: 1867-66-9)
    KETAMINE Nomination TABLE OF CONTENTS Page 1.0 BASIS OF NOMINATION 1 2.0 BACKGROUND INFORMATION 1 3.0 CHEMICAL PROPERTIES 2 3.1 Chemical Identification 2 3.2 Physico-Chemical Properties 3 3.3 Purity and Commercial Availability 4 4.0 PRODUCTION PROCESSES AND ANALYSIS 6 5.0 PRODUCTION AND IMPORT VOLUMES 7 6.0 USES 7 7.0 ENVIRONMENTAL OCCURRENCE 7 8.0 HUMAN EXPOSURE 7 9.0 REGULATORY STATUS 7 10.0 CLINICAL PHARMACOLOGY 7 11.0 TOXICOLOGICAL DATA 13 11.1 General Toxicology 13 11.2 Neurotoxicology 14 12.0 CONCLUSIONS 15 APPENDIX A 17 APPENDIX B 23 APPENDIX C 27 1 KETAMINE 1.0 BASIS OF NOMINATION Ketamine, a noncompetitive NMDA receptor blocker, has been used extensively off - label as a pediatric anesthetic for surgical procedures in infants and toddlers. Recently, Olney and coworkers have demonstrated severe widespread apoptotic degeneration throughout the rapidly developing brain of the 7-day-old rat after ketamine administration. Recent research at FDA has confirmed and extended Olney’s observations. These findings are cause for concern with respect to ketamine use in children. The issue of whether the neurotoxicity found in this animal model (rat) has scientific and regulatory relevance for the pediatric use of ketamine relies heavily upon confirmation of these findings that may be obtained from the conduct of an appropriate study in non-human primates. 2.0 BACKGROUND INFORMATION The issue of potential ketamine neurotoxicity in children surfaced as a result of FDA’s reluctance to approve an NIH pediatric clinical trial using this compound because of its documented neurotoxic effects in young rats (published in several papers over the last ten years by Olney and co-workers).
    [Show full text]
  • The Anticholinergic Toxidrome
    Poison HOTLINE Partnership between Iowa Health System and University of Iowa Hospitals and Clinics July 2011 The Anticholinergic Toxidrome A toxidrome is a group of symptoms associated with poisoning by a particular class of agents. One example is the opiate toxidrome, the triad of CNS depression, respiratory depression, and pinpoint pupils, and which usually responds to naloxone. The anticholinergic toxidrome is most frequently associated with overdoses of diphenhydramine, a very common OTC medication. However, many drugs and plants can produce the anticholinergic toxidrome. A partial list includes: tricyclic antidepressants (amitriptyline), older antihistamines (chlorpheniramine), Did you know …… phenothiazines (promethazine) and plants containing the anticholinergic alkaloids atropine, hyoscyamine and scopolamine (Jimson Weed). Each summer, the ISPCC receives approximately 10-20 The mnemonic used to help remember the symptoms and signs of this snake bite calls, some being toxidrome are derived from the Alice in Wonderland story: from poisonous snakes (both Blind as a Bat (mydriasis and inability to focus on near objects) local and exotic). Red as a Beet (flushed skin color) Four poisonous snakes can be Hot as Hades (elevated temperature) found in Iowa: the prairie These patients can sometimes die of agitation-induced hyperthermia. rattlesnake, the massasauga, Dry as a Bone (dry mouth and dry skin) the copperhead, and the Mad as a Hatter (hallucinations and delirium) timber rattlesnake. Each Bowel and bladder lose their tone (urinary retention and constipation) snake has specific territories Heart races on alone (tachycardia) within the state. ISPCC A patient who has ingested only an anticholinergic substance and is not specialists have access to tachycardic argues against a serious anticholinergic overdose.
    [Show full text]
  • 3 Drugs That May Cause Delirium Or Problem Behaviors CARD 03 19 12 JUSTIFIED.Pub
    Drugs that May Cause Delirium or Problem Behaviors Drugs that May Cause Delirium or Problem Behaviors This reference card lists common and especially problemac drugs that may Ancholinergics—all drugs on this side of the card. May impair cognion cause delirium or contribute to problem behaviors in people with demena. and cause psychosis. Drugs available over‐the‐counter marked with * This does not always mean the drugs should not be used, and not all such drugs are listed. If a paent develops delirium or has new problem Tricyclic Andepressants Bladder Anspasmodics behaviors, a careful review of all medicaons is recommended. Amitriptyline – Elavil Darifenacin – Enablex Be especially mindful of new medicaons. Clomipramine – Anafranil Flavoxate – Urispas Desipramine – Norpramin Anconvulsants Psychiatric Oxybutynin – Ditropan Doxepin – Sinequan Solifenacin – VESIcare All can cause delirium, e.g. All psychiatric medicaons should be Imipramine – Tofranil Tolterodine – Detrol Carbamazepine – Tegretol reviewed as possible causes, as Nortriptyline – Aventyl, Pamelor Gabapenn – Neuronn effects are unpredictable. Trospium – Sanctura Anhistamines / Allergy / Leveracetam – Keppra Notable offenders include: Insomnia / Sleep Valproic acid – Depakote Benzodiazepines e.g. Cough & Cold Medicines *Diphenhydramine – Sominex, ‐Alprazolam – Xanax *Azelasne – Astepro Pain Tylenol‐PM, others ‐Clonazepam – Klonopin *Brompheniramine – Bromax, All opiates can cause delirium if dose *Doxylamine – Unisom, Medi‐Sleep ‐Lorazepam – Avan Bromfed, Lodrane is too high or
    [Show full text]
  • Medicare Part D Excluded Drug List
    MEDICARE PART D EXCLUDED DRUGS LIST 2016_updated July 2016 Reason: LIST = multiple reasons it's excluded; "not covered under Part D law" Reason: Not properly listed with FDA = CMS considers it best practice for Part D sponsors to consider the proper listing of a drug product with the FDA as a prerequisite for making a Part D drug coverage determination. The FDA is unable to provide regulatory status determinations through their regular processes if a drug product is not properly listed. Therefore, Part D sponsors should begin the drug coverage determination process by confirming that a prescription drug product national drug code (NDC) is properly listed with the FDA. Reason: DESI = Less Than Effective (LTE) drug for ALL indications Label Name Reason 1ST BASE CRE Bulk Ingredient 2-FUCCOSYLLA PAK LACTO-N Medical Food ABANEU-SL SUB Vitamin/Mineral ABLAVAR INJ 244MG/ML Diagnostic Agent ACACIA EXTRA SOL 1:20 Non-standardized allergenic ACCUCAINE INJ 1% LIST ACD FORMULA SOL A Blood Component ACD-A SOL Blood Component ACLARO PD EMU 4% Cosmetic ACREMONIUM SOL 20000PNU Non-standardized allergenic ACTCT FLEX 3 PAD 4"X4" Not properly listed with FDA ACTHREL INJ 100MCG Diagnostic Agent ACTI ANTIMIC PAD 2"X2" Not properly listed with FDA ACTI ANTIMIC PAD 4"X4" Not properly listed with FDA ACTICOAT 7 PAD 2"X2" Not properly listed with FDA ACTICOAT 7 PAD 4"X5" Not properly listed with FDA ACTICOAT ABS PAD 4"X5" Not properly listed with FDA ACTICOAT MOI PAD 2"X2" Surgical Supply/Medical ACTICOAT MOI PAD 4"X4" Surgical Supply/Medical ACTICOAT MOI PAD
    [Show full text]
  • Hyoscyamine, Atropine, Scopolamine, and Phenobarbital
    PATIENT & CAREGIVER EDUCATION Hyoscyamine, Atropine, Scopolamine, and Phenobarbital This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Donnatal; Phenohytro What is this drug used for? It is used to treat irritable bowel syndrome. It is used to treat ulcer disease. It may be given to your child for other reasons. Talk with the doctor. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child has any of these health problems: Heart problems due to bleeding, bowel block, enlarged colon, glaucoma, a hernia Hyoscyamine, Atropine, Scopolamine, and Phenobarbital 1/9 that involves your stomach (hiatal hernia), myasthenia gravis, slow-moving GI (gastrointestinal) tract, trouble passing urine, or ulcerative colitis. If your child has ever had porphyria. If your child has been restless or overexcited in the past after taking phenobarbital. If your child is addicted to drugs or alcohol, or has been in the past. This is not a list of all drugs or health problems that interact with this drug. Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe to give this drug with all of your child’s other drugs and health problems.
    [Show full text]
  • Hb 185 an Act Listing Synthetic
    62nd Legislature HB0185 AN ACT LISTING SYNTHETIC MARIJUANA AND SALVIA AS DANGEROUS DRUGS; REQUIRING RULEMAKING BY THE DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES; PROVIDING PENALTIES; AMENDING SECTIONS 44-12-102, 45-9-101, 45-9-102, 45-9-110, 50-31-306, 50-31-310, AND 50-32-222, MCA; AND PROVIDING AN IMMEDIATE EFFECTIVE DATE. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA: Section 1. Section 44-12-102, MCA, is amended to read: "44-12-102. Things subject to forfeiture. (1) The following are subject to forfeiture: (a) all controlled substances that have been manufactured, distributed, prepared, cultivated, compounded, processed, or possessed in violation of Title 45, chapter 9; (b) all money, raw materials, products, and equipment of any kind that are used or intended for use in manufacturing, preparing, cultivating, compounding, processing, delivering, importing, or exporting any controlled substance in violation of Title 45, chapter 9, except items used or intended for use in connection with quantities of marijuana in amounts less than 60 grams; (c) except as provided in subsection (2)(d), all property that is used or intended for use as a container for anything enumerated in subsection (1)(a) or (1)(b); (d) except as provided in subsection (2), all conveyances, including aircraft, vehicles, and vessels, that are used or intended for use in any manner to facilitate the commission of a violation of Title 45, chapter 9; (e) all books, records, and research products and materials, including formulas, microfilm, tapes, and data,
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Trends in Prescription Medication Use Among Children and Adolescents— United States, 1999-2014
    Supplementary Online Content Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents— United States, 1999-2014. JAMA. doi:10.1001/jama.2018.5690 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class This supplementary material was provided by the authors to give readers additional informtion about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class Therapeutic classes are based on the Lexicon Plus prescription medication database and only those classes reported in the manuscript are listed. ADHD Medications Antiadrenergic Agents, Centrally Acting Clonidine Guanfacine CNS Stimulants Amphetamines Amphetamine Amphetamine; Dextroamphetamine Dextroamphetamine Lisdexamfetamine Methylphenidate or Dexmethylphenidate Dexmethylphenidate Methylphenidate Other CNS Stimulant Pemoline Selective Norepinephrine Reuptake Inhibitor Atomoxetine Antibiotics Cephalosporins Cefadroxil Cephalexin Cefaclor Cefprozil Cefuroxime Loracarbef Cefdinir Cefditoren Cefixime Cefpodoxime Ceftibuten Ceftriaxone Glycopeptide Antibiotics Vancomycin H. Pylori Eradication Agents Amoxicillin; Clarithromycin; Lansoprazole Lincomycin Derivatives Clindamycin Macrolide Derivatives Telithromycin Azithromycin Clarithromycin
    [Show full text]